Skip to main content
. 2010 Jul 27;285(41):31472–31483. doi: 10.1074/jbc.M110.129213

FIGURE 7.

FIGURE 7.

Quantifying the efficacy of the 10-mer peptide agonist toward wild type and mutant C5aRs. Left panel, maximal signaling stimulated in wild type, S272A, S30C/S272A, and S30C/S272C mutant C5aRs in response to ∼10 μm peptide agonist. Vector represents the β-galactosidase activity of the engineered yeast in the absence of both receptor and ligand. Each bar represents means ± S.D. of signaling activity for three independent transformants, and data are representative of at least two independent experiments. Right panel, dose-dependent signaling stimulated by the 10-mer peptide agonist in wild type, S272A, S30/S272A, and S30C/S272C mutant C5aRs. y axis represents β-galactosidase activity normalized to the maximum signaling, and each point represents means ± S.D. of signaling activity for three independent transformants, and data are representative of at least two independent experiments.